AstraZeneca to Promote Chinese Patent Medicine

AstraZeneca to Promote Chinese Patent Medicine

2019/1/25

Chinese pharmaceutical major Luye Pharma Group Ltd announced on January 16 that it had signed an agreement with AstraZeneca China for the latter to have exclusive rights to promote its Xuezhikang capsule medicine in the Chinese mainland. According to the agreement, Luye Pharma will retain the asset rights, commercial sales rights, the registration permit, all intellectual property rights and other product-related rights, aside from product promotion rights. The cooperation signifies increasing recognition of Chinese patent medicine and will promote such medicines' image internationally as drugs suitable for disease treatment, instead of simply being healthcare supplements, said Yu Zhibin, traditional Chinese medicine department director with the China Chamber of Commerce for Import and Export of Medicine and Health Products.

Source: Chinadaily




People watch


It is lucky for Chen Jun to began his career in the IP industry 14 years ago when the first group of IP managers for businesses appeared on the stage in China and he has been in the industry.

It was this “Whampoa Military Academy” for IP that educated China’s first batch of corporate IP management personnel. Many of these engineers left Foxconn in the years since.